Kurz gefasst
Editorial in der Zeitschrift JAMA, 2024. Verfasst von Janet Freilich und 1 weiteren Autor:innen. Beteiligte Einrichtung: Boston University School of Law, Boston, Massachusetts. Hauptthemen laut MEDLINE: Patents as Topic, Prescription Drugs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint summarizes the role of the Patent Trial and Appeal Board (PTAB) in reforming the drug patent process to avoid erroneously granted patents; highlights how other reform efforts, such as the PREVAIL Act, actually weaken the PTAB; and suggests changes to strengthen the PTAB and promote generic availability and reduced health care costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Boston University School of Law, Boston, Massachusetts.
- The Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Freilich, J., & Kesselheim, A. S. (2024). The Patent Trial and Appeals Board. JAMA. https://doi.org/10.1001/jama.2024.15510
Vancouver
Freilich J, Kesselheim AS. The Patent Trial and Appeals Board. JAMA. 2024. doi:10.1001/jama.2024.15510
BibTeX
@article{Freilich2024,
author = {Freilich, Janet and Kesselheim, Aaron S},
title = {The Patent Trial and Appeals Board},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.15510}
}
EUVIMED